MDNA Life Sciences Appoints George Steinfels, Ph.D., MBA, as President and Interim CEO
Jupiter, FL, November 16, 2014 – MDNA Life Sciences Inc., a molecular diagnostics company pioneering the development of diagnostic tests based on the mitochondrial genome, announced today the appointment of George Steinfels, Ph.D., MBA, as the Company’s President and Interim Chief Executive Officer.
Dr. Steinfels, who joined MDNA’s Board of Directors earlier this month, will oversee the imminent acquisition of the intellectual property and assets of Mitomics Inc., including the tissue-based Prostate Core Mitomic Test™, as well as the proprietary Mitomic Technology™ platform, which MDNA will utilize to develop low-cost, blood-based molecular diagnostic tests offering market-leading accuracy. In addition, Dr. Steinfels will establish an executive team to augment future sales of the Prostate Core Mitomic Test™ and manage multiple planned product launches for its novel blood-based tests for prostate cancer, endometriosis, ovarian cancer and lung cancer.
MDNA Chairman Harry Smart said, “We believe George’s science pedigree and biotech product launch experience make him well equipped to build a solid foundation for the success of MDNA Life Sciences and our pipeline of potentially market-disruptive molecular diagnostics based on the mitochondrial genome.”
Dr. Steinfels has more than 25 years’ experience in the life sciences industry. He has held executive and C-level positions in both public and private companies ranging in size from small startups to multi-national pharmaceutical and Contract Research Organizations. He has also held numerous board positions with diagnostic and genomic testing companies. Dr. Steinfels has hands-on experience in virtually every aspect of product development beginning with bench research, first-in-man through pivotal clinical, regulatory submissions and product launch and line extensions. He has written and published extensively and has spoken at business conferences on various topics in the medical technology industry.
About MDNA Life Sciences
MDNA Life Sciences, Inc., is pioneering the development of molecular diagnostic tests based on the mitochondrial genome. The company’s revenue-generating Prostate Core Mitomic Test™ (PCMT™) is the highest performing tissue-based prostate cancer diagnostic on the market with a significantly greater tumor field effect that allows 85% sensitivity and 92% negative predictive value. MDNA is applying its expertise in mitochondrial genomics to developing an extensive and proprietary portfolio of blood-based molecular tests in conditions that are currently dependent on poor or absent screening tests or invasive procedures for detection. Blood-based diagnostic tests for prostate cancer and endometriosis are in late stage development. For more information visit www.mdnalifesciences.com.